Zero Treatments for 5,000 Patients: Until Maybe Now
Friedreich's ataxia affects 5,000 Americans with zero approved disease-modifying treatments. Larimar Therapeutics just earned FDA Breakthrough Therapy Designation for a drug that restored frataxin to carrier levels and improved all four clinical measures, and they're filing for approval in June.
Imagine you're diagnosed with a disease that slowly robs you of your ability to walk, talk, and eventually breathe. Now imagine your doctor tells you there's nothing (literally nothing) approved to slow it down.
That's Friedreich's ataxia in 2026. About 5,000 people in the U.S. live with this rare neurodegenerative disease, and not a single one of them has access to a treatment that modifies the underlying condition. There are therapies for symptoms, sure. But something that actually fights the disease at its root? Zero.
Until, possibly, now.
Larimar Therapeutics just scored FDA Breakthrough Therapy Designation for its drug nomlabofusp, and the data behind it might be the most exciting thing this disease community has ever seen.
The Protein Your Body Forgot How to Make
Friedreich's ataxia is caused by a genetic mutation that starves your cells of a protein called frataxin. Think of frataxin like oil in an engine. Without enough of it, the mitochondria (your cells' power plants) grind down. Nerves degrade. The heart weakens. Muscles lose coordination. It's a slow, relentless decline that typically begins in childhood.
Larimar's approach is beautifully straightforward: if the body can't make enough frataxin, deliver it directly. Nomlabofusp is a fusion protein that shuttles frataxin right into the mitochondria where it's needed. It's less like a traditional drug and more like a biological FedEx package addressed to the exact organelle that's failing.
The Numbers That Got the FDA's Attention
In Larimar's ongoing open-label study, patients treated with nomlabofusp for one year saw their skin frataxin levels rise to the range expected in asymptomatic carriers, people who carry the Friedreich's ataxia mutation but never develop symptoms. Earlier in development, the 25 mg daily dose pushed frataxin to about 70% of healthy levels in skin cells after just 90 days.
That's a big deal. Carriers live totally normal lives. Getting a patient's frataxin up to carrier territory is like refilling that engine oil to the point where things actually start running smoothly again.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
But frataxin levels alone aren't enough to get the FDA excited. What sealed the Breakthrough designation was that patients showed consistent improvement across all four clinical measures after a year of treatment. Those included tests of coordination, daily living activities, hand dexterity, and fatigue. In a disease where the natural trajectory points relentlessly downward, any improvement, let alone across the board, turns heads.
The Regulatory Fast Lane
Breakthrough Therapy Designation isn't just a gold star on your fridge. It's a genuine accelerator. The FDA assigns senior reviewers, provides intensive guidance, and opens the door to rolling submissions and priority review. Since 2015, 88% of new drug and biologic approvals used at least one of the FDA's expedited programs. Larimar just earned its ticket to ride.
The company is targeting a BLA filing in June 2026: that's the formal application to get nomlabofusp approved. The twist? They're seeking accelerated approval, which lets the FDA greenlight a drug based on a surrogate endpoint rather than waiting years for traditional clinical outcomes. In this case, the surrogate is skin frataxin levels.
The FDA agreed that skin frataxin is "reasonably likely to predict clinical benefit." That's regulator-speak for: we believe restoring this protein should translate into real improvements for patients. A confirmatory Phase 3 trial will begin screening patients in Q2 2026, running in parallel to provide the longer-term data the FDA will eventually want.
If everything stays on track, Larimar is eyeing a U.S. launch in the first half of 2027.
The Elephant in the Room: Anaphylaxis
No story this promising comes without a "but." And this is an important one.
Of the 39 participants in the long-term open-label study, seven experienced anaphylaxis after receiving nomlabofusp. That's roughly 18%, a rate that will absolutely draw scrutiny during the BLA review. The FDA has already flagged the adequacy of the safety database as an area requiring careful examination.
Anaphylaxis is manageable in a clinical setting with proper monitoring and protocols. But for a therapy that patients would take long-term, it's the kind of thing regulators won't brush past. Larimar will need to demonstrate robust risk mitigation strategies and potentially a large enough safety dataset to satisfy reviewers.
A Crowded, But Still Empty, Playing Field
Larimar isn't the only company chasing a Friedreich's ataxia treatment, but it might be the furthest along right now. Lexeo Therapeutics is developing a gene therapy called LX2006 that also earned Breakthrough Therapy Designation back in July 2025, with a pivotal study planned for early 2026. Voyager Therapeutics, partnered with Neurocrine Biosciences, expects to begin clinical testing of its own gene therapy this year.
Retrotope has RT001 in Phase 3, and Minoryx Therapeutics is running Phase 2 work with leriglitazone. All told, more than 10 companies are developing pipeline therapies for this disease.
But competition is actually welcome news for patients who've had nothing for decades. The more shots on goal, the better the odds that something crosses the finish line. And right now, Larimar's nomlabofusp looks like the closest to doing exactly that.
What It All Means
Friedreich's ataxia has been one of biotech's most stubborn orphan diseases: small patient population, complex biology, and a frustrating history of failed approaches. PTC Therapeutics' vatiquinone stumbled, leaving Biogen's Skyclarys as the nearest comparison in the broader ataxia space but not addressing Friedreich's specifically.
Larimar's story is the kind that makes rare disease drug development worth watching. A tiny company, born from a 2018 merger, licensed technology from Children's Hospital of Philadelphia, survived a clinical hold, burned through roughly $95 million in R&D expenses in just the first nine months of 2025, and now stands on the doorstep of potentially delivering the first disease-modifying treatment to a community that has waited for one their entire lives.
The BLA filing is four months away. The data readout is coming in Q2. And 5,000 patients are paying very close attention.
For once, they might actually have a reason to.
Deals and Strategy
5 min read
The Cancer Drug That Plays Dead Until It Finds Its Target
Astellas just dropped $335 million upfront on a cancer drug that stays completely dormant until it reaches the tumor; then it wakes up and attacks. The early data on VIR-5500 is turning heads, and the deal's timing tells you everything about Astellas' post-XTANDI anxiety.
